Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Bavencio First Immunotherapy Drug Approved for Merkel-Cell Carcinoma

June 2017 Vol 3 No 3

On March 23, 2017, the FDA accelerated the approval of a new PD-L1 inhibitor, Bavencio (avelumab; from EMD Serono/Pfizer), for the treatment of patients with metastatic Merkel-cell carcinoma, a rare type of cancer. This is the first non-chemotherapy drug and the first immunotherapy approved by the FDA for Merkel-cell carcinoma. It is intended to be used in patients aged 12 years or older.

“While skin cancer is one of the most common cancers, patients with a rare form called Merkel cell cancer have not had an approved treatment option until now. The scientific community continues to make advances targeting the body’s immune system mechanisms for the treatment of various types of cancer. These advancements are leading to new therapies–even in rare forms of cancer where treatment options are limited or non-existent,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

In the clinical trial that led to the FDA approval, 33% of patients had their tumor shrink partially or entirely, and this lasted for more than 6 months in 86% of the patients and more than 12 months in 45% of the patients.

Common side effects of Bavencio include fatigue, musculoskeletal pain, diarrhea, nausea, rash, reduced appetite, and swelling of the limbs. The most common serious risks of Bavencio are immune-related, where the body’s immune system attacks healthy cells or organs, such as the lungs, liver, colon, glands, and kidneys. In addition, there is a risk of serious infusion-related reactions. Patients who have severe or life-threatening infusion-related reactions should stop using Bavencio.

Bavencio is administered as an intravenous infusion every 2 weeks.

Recommended For You